Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis
Completed · Phase 2
Conditions studied: Idiopathic Pulmonary Fibrosis
In brief
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Key facts
- Study ID
- NCT01262001
- Run by
- Kyntra Bio
- People needed
- 90
- Starts
- 2011-03-01
- Expected to finish
- 2017-06-21
- Last updated by the study team
- 2019-10-09
Who can join
Age: 35 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham Hospital — Birmingham, Alabama, United States
- Arizona Pulmonary Specialists, LTD — Scottsdale, Arizona, United States
- Yale University — New Haven, Connecticut, United States
- Central Florida Pulmonary Group, PA — Orlando, Florida, United States
- Tampa General Hospital — Tampa, Florida, United States
- Emory University — Atlanta, Georgia, United States
- Via Christi Hospitals Wichita, Inc. — Wichita, Kansas, United States
- University of Louisville — Louisville, Kentucky, United States
- St. Luke's Hospital — Chesterfield, Missouri, United States
- Rutgers-Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States
- Mount Sinai — New York, New York, United States
- The Ohio State University — Columbus, Ohio, United States
- Vanderbilt University — Nashville, Tennessee, United States
- University of Texas Southwestern Medical Center — Dallas, Texas, United States
- University of Utah - Lung Health Research — Salt Lake City, Utah, United States
- Vermont Lung Center — Colchester, Vermont, United States
- Inova Fairfax Hospital — Falls Church, Virginia, United States
- University of Wisconsin School of Medicine & Public Health — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.